Skip to main content

Table 1 SELDI-TOF MS protein peaks differentially expressed in paired sera from SJIA before and after therapy

From: Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy

 

Before/after conventional therapy

Before/after MRA

Mass (m/z)

P

Patients with visually distinct peaks/total no. of patients

P

Patients with visually distinct peaks/total no. of patients

4504

0.0001

 

0.005

 

4758

0.0005

 

0.0006

 

5739

0.0001

 

0.00000008

 

6441

0.00009

 

0.0001

 

6947

0.0005

 

0.003

 

9510

0.0007

6/8

0.00001

12/15

9725

0.00006

 

0.00001

 

11405

0.00001

8/8

0.000000003

14/15

11520

0.000007

8/8

0.000000001

14/15

11641

0.000005

8/8

0.0000000001

14/15

11718

0.0004

 

0.00002

 

11880

0.0002

 

0.0000006

 

12703

0.0006

7/8

0.04

6/15

20816

0.0002

7/8

0.01

9/15

22389

0.0002

 

0.00005

 

23627

0.0002

 

0.09

 

28734

0.0002

 

0.00006

 

33457

0.00001

6/8

0.00001

11/15

66637

0.0001

7/8

0.000009

11/15

74886

0.0006

 

0.00003

 

75622

0.0009

 

0.0001

 

76319

0.0008

 

0.00002

 

79216

0.0007

 

0.000003

 
  1. Differences between mass spectra of sera before and after conventional therapy. Sera from eight patients with SJIA who responded to conventional therapy were analyzed before and after therapy by SELDI-TOF MS using Ciphergen IMAC-3 copper chips. All samples were run in duplicate. Only variables with nonparametric P values of <0.001 are given. Of 282 spectral peaks identified, the 23 listed here had mean signal intensities significantly different (P < 0.001) before and after response to treatment. Proteins are listed according to mass/charge ratio. Visually distinct peaks (in bold type) refers to peaks that were clearly different between paired samples from before and after treatment upon visual inspection of the profiles, as shown in Fig. 1. The numbers of patients in whom these peaks were visually distinct are shown in columns 3 and 5. These peaks represent potential biomarkers of active disease. IMAC-3, immobilized metal affinity capture; MRA, humanized anti-IL-6 receptor monoclonal antibody; SELDI-TOF MS, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry; SJIA, systemic juvenile idiopathic arthritis.